Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.

Immunome, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (IMMUNOME) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE PRICING OF AN UNDERWRITTEN PUBLIC OFFERING OF 18,625,000 SHARES OF ITS COMMON STOCK AT A PRICE TO THE PUBLIC OF $21.50 PER SHARE. ALL OF THE SHARES ARE TO BE SOLD BY IMMUNOME. THE GROSS PROCEEDS TO IMMUNOME FROM THE OFFERING, BEFORE DEDUCTING UNDERWRITING DISCOUNTS AND COMMISSIONS AND OTHER OFFE.

IMMUNOME ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (IMMUNOME) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED ITS PLANS TO COMMENCE AN UNDERWRITTEN PUBLIC OFFERING, SUBJECT TO MARKET AND OTHER CONDITIONS, TO ISSUE AND SELL $400 MILLION OF SHARES OF ITS COMMON STOCK. ALL OF THE SHARES ARE BEING OFFERED BY IMMUNOME. IN CONNECTION WITH THE PROPOSED OFFERING, IMMUNOME EXPECTS TO GRANT THE UNDERWRITERS A 30-DAY.

IMMUNOME ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY COMMITTED TO DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED POSITIVE TOPLINE RESULTS FROM THE GLOBAL PIVOTAL PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR (GSI), IN PATIENTS WITH PROGRESSING DESMOID TUMORS. THE TRIAL MET ITS PRIMARY ENDPOINT OF IMPROVING PROGRESSION-FREE SURVIVAL, DEMONSTRATING A STATISTICALLY SI.

IMMUNOME ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT IN PATIENTS WITH DESMOID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THE COMPANY WILL HOST A CONFERENCE CALL AND WEBCAST ON MONDAY, DECEMBER 15, 2025 AT 8:30 AM ET TO DISCLOSE THE TOPLINE RESULTS FROM THE GLOBAL PIVOTAL PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT, AN INVESTIGATIONAL, ORAL, ONCE-DAILY GAMMA SECRETASE INHIBITOR, IN PATIENTS WITH PROGRESSING DESMOID TUMORS. WEBCAST, PRES.

IMMUNOME TO ANNOUNCE TOPLINE RESULTS FROM PHASE 3 RINGSIDE TRIAL OF VAREGACESTAT IN PATIENTS WITH DESMOID TUMORS

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON DECEMBER 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 88,000 SHARES OF COMMON STOCK TO FOUR NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDU.

IMMUNOME REPORTS INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT MEMBERS OF IMMUNOME'S MANAGEMENT WILL PARTICIPATE IN THE FOLLOWING INVESTOR CONFERENCES: PIPER SANDLER 37TH ANNUAL HEALTHCARE CONFERENCE PRESENTATION DATE/TIME: DECEMBER 3, 2025, AT 9 A.M. ET 8TH ANNUAL EVERCORE HEALTHCARE CONFERENCE PRESENTATION DATE/TIME: DECEMBER 3, 2025, AT 9:10 A.M. ET INTERESTED PARTI.

IMMUNOME TO PRESENT AT UPCOMING INVESTOR CONFERENCES

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE QUARTER ENDED SEPTEMBER 30, 2025, AND PROVIDED A BUSINESS UPDATE. IMMUNOME'S PIPELINE CONTINUES TO ADVANCE, SAID CLAY B. SIEGALL, PH.D., PRESIDENT AND CHIEF EXECUTIVE OFFICER OF IMMUNOME. WE ANTICIPATE THE RELEASE OF TOPLINE DATA FOR THE RINGSIDE TRIAL OF VAREGACESTAT BEFORE THE END.

IMMUNOME REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON NOV. 3, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NONSTATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 19,000 SHARES OF COMMON STOCK TO THREE NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEME.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, TODAY ANNOUNCED THAT IMMUNOME MANAGEMENT WILL PRESENT AT THE 2ND ANNUAL GUGGENHEIM HEALTHCARE INNOVATION CONFERENCE ON TUESDAY, NOV. 11, 2025 AT 8:30 A.M. ET. INTERESTED PARTIES CAN ACCESS THE LIVE AUDIO WEBCAST FOR THIS CONFERENCE FROM THE INVESTOR RELATIONS SECTION OF THE COMPANY'S WEBSITE AT WWW.IMMUNOME.COM. THE WEBCAST REP.

IMMUNOME TO PRESENT AT 2ND ANNUAL GUGGENHEIM HEALTHCARE INNOVATION CONFERENCE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, RECENTLY PRESENTED PRECLINICAL DATA SHOWING ITS PROPRIETARY ANTIBODY-DRUG CONJUGATE (ADC) PAYLOAD HC74 OVERCOMES MULTIPLE MECHANISMS OF ADC RESISTANCE, INCLUDING PAYLOAD EFFLUX AND TARGET HETEROGENEITY. HC74 IS A NOVEL TOPOISOMERASE I INHIBITOR THAT SERVES AS THE PAYLOAD IN IM-1021, A ROR1-TARGETED ADC CURRENTLY IN A PHASE 1 TR.

IMMUNOME PRESENTS PRECLINICAL DATA SHOWING PROPRIETARY TOP1I ADC PAYLOAD HC74 OVERCOMES MULTIPLE MECHANISMS OF ADC RESISTANCE

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON OCT. 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 69,000 SHARES OF COMMON STOCK TO 5 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMENT.

ALAMEDA, CALIF.--(BUSINESS WIRE)-- #ANTIBODIES--INFINIMMUNE ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOME.

INFINIMMUNE ANNOUNCES RESEARCH COLLABORATION WITH IMMUNOME

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON SEPT. 2, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 117,000 SHARES OF COMMON STOCK TO 8 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMEN.

BOTHELL, WASH.--(BUSINESS WIRE)--IMMUNOME, INC. (THE COMPANY) (NASDAQ: IMNM), A BIOTECHNOLOGY COMPANY FOCUSED ON DEVELOPING FIRST-IN-CLASS AND BEST-IN-CLASS TARGETED CANCER THERAPIES, ANNOUNCED TODAY THAT ON AUG. 1, 2025, THE COMPENSATION COMMITTEE OF THE COMPANY'S BOARD OF DIRECTORS (THE COMPENSATION COMMITTEE) GRANTED INDUCEMENT AWARDS CONSISTING OF NON-STATUTORY STOCK OPTIONS TO PURCHASE AN AGGREGATE OF 39,000 SHARES OF COMMON STOCK TO 5 NEW EMPLOYEES UNDER THE COMPANY'S 2024 INDUCEMENT.

Immunome, Inc.

IMNM

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Immunome, Inc.

IMNM.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

IMNM